Binding to Bridging: Complete Suite of FcγR Assay Tools Accelerates Antibody Therapeutic Development

Presented by: Gopal Krishnan, Promega Corporation Poster Number: P-207-Th Poster Session: Characterizing, Bridging and Improving Bioassays Thursday, 25 Sept. at 10:30 ----- Antibodies are effective therapeutics because of their specificity in binding to an antigen and ability to activate an immune response through effector functions like antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell phagocytosis (ADCP). We developed a suite of luminescent assays for characterizing antibody effector functions that can be run by as a service for end-to-end characterization of Fc gamma to measure binding, receptor activation, and target cell killing.